<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004804</url>
  </required_header>
  <id_info>
    <org_study_id>199/11964</org_study_id>
    <secondary_id>TUMC-M1260</secondary_id>
    <nct_id>NCT00004804</nct_id>
  </id_info>
  <brief_title>Phase III Randomized Study of High Vs Standard Dose of Interferon Alfa for Chronic Hepatitis C</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tulane University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Office of Rare Diseases (ORD)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Determine whether the initial response to interferon alfa (IFN-A) can be&#xD;
      increased by starting at a dose of 5 MU three times a week in patients with chronic hepatitis&#xD;
      C.&#xD;
&#xD;
      II. Determine whether patients who had normalized alanine aminotransferase (ALT) levels can&#xD;
      maintain normal ALT during stepwise dose reduction from 5 MU to 3 MU to 1.5 MU.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: Patients are randomly assigned to 1 of 2 treatment groups in a 2:1 ratio.&#xD;
&#xD;
      The first group is treated with high-dose interferon alfa (IFN-A) administered subcutaneously&#xD;
      twice a week for 12 weeks. If the alanine aminotransferase (ALT) level has normalized, the&#xD;
      IFN-A dose is decreased in a stepwise fashion. If the ALT level decreases by more than 50%,&#xD;
      IFN-A is continued at the same dose until week 24 or the ALT normalizes. If the ALT level&#xD;
      decreases by less than 50%, treatment is discontinued.&#xD;
&#xD;
      The second group is treated with standard-dose IFN-A administered subcutaneously twice a week&#xD;
      for 24 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1993</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>57</enrollment>
  <condition>Hepatitis C</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>interferon alfa</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
          -  Biopsy-proven chronic hepatitis Anti-hepatitis C virus positive Hepatitis B surface&#xD;
             antigen negative&#xD;
&#xD;
          -  No decompensated cirrhosis&#xD;
&#xD;
        --Prior/Concurrent Therapy--&#xD;
&#xD;
          -  No concurrent immunosuppressives At least 1 year since interferon&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
          -  Hepatic: No other cause of liver disease&#xD;
&#xD;
          -  Other: Not HIV positive&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>0 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna S. F. Lok</last_name>
    <role>Study Chair</role>
    <affiliation>Tulane University School of Medicine</affiliation>
  </overall_official>
  <verification_date>February 1997</verification_date>
  <study_first_submitted>February 24, 2000</study_first_submitted>
  <study_first_submitted_qc>February 24, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2000</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>hepatitis C</keyword>
  <keyword>immunologic disorders and infectious disorders</keyword>
  <keyword>rare disease</keyword>
  <keyword>viral infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

